Maastricht II treatment scheme and efficacy of different proton pump inhibitors in eradicating Helicobacter pylori

被引:43
作者
Altintas, Engin [1 ]
Sezgin, Orhan [1 ]
Ulu, Oguz [2 ]
Aydin, Ozlem [3 ]
Camdeviren, Handan [4 ]
机构
[1] Mersin Univ, Fac Med, Dept Gastroenterol, Mersin, Turkey
[2] Mersin Univ, Fac Med, Dept Internal Med, Mersin, Turkey
[3] Mersin Univ, Fac Med, Dept Pathol, Mersin, Turkey
[4] Mersin Univ, Fac Med, Dept Biostat, Mersin, Turkey
关键词
D O I
10.3748/wjg.v10.i11.1656
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
AIM: The Maastricht II criteria suggest the use of amoxicillin and clarithromycin in addition to a proton pump inhibitor over 7-10 d as a first line therapy in the eradication of Helicobacter pylori (H pylori). For each proton pump inhibitor, various rates of eradication have been reported. The present study was to compare the efficacy of different proton pump inhibitors like omeprazole, lansoprazole and pantoprazole in combination with amoxicillin and clarithromycin in the first line eradication of H pylori and to investigate the success of H pylori eradication in our district. METHODS: A total of 139 patients were included having a Helicobacter pylori (+) gastroduodenal disorders diagnosed by means of histology and urease test. Besides amoxicillin (1 000 mg twice a day) and clarithromycin (500 mg twice a day), they were randomized to take omeprazole (20 mg twice a day), or lansoprazole (30 mg twice a day), or pantoprozole (40 mg twice a day) for 14 d. Four weeks after the therapy, the eradication was assessed by means of histology and urease test. It was evaluated as eradicated if the H pylori was found negative in both. The complaints (pain in epigastrium, nocturnal pain, pyrosis and bloating) were graded in accordance with the Licert scale. The compliance of the patients was recorded. RESULTS: The eradication was found to be 40.8% in the omeprazole group, 43.5% in the lansoprazole group and 47.4% in the pantoprazole group. Sixty-three out of 139 patients (45%) had eradication. No statistically significant difference was observed between the groups. Significant improvements were seen in terms of the impact on the symptom scores in each group. CONCLUSION: There was no difference between omeprazole, lansoprazole and pantoprazole in H pylori eradication, and the rate of eradication was as low as 45%. Symptoms were improved independent of the eradication in each treatment group. The low eradication rates suggest that the antibiotic resistance or the genetic differences of the microorganism might be in effect. Further studies are required to verify these suggestions.
引用
收藏
页码:1656 / 1658
页数:3
相关论文
共 31 条
[1]  
Bazzoli F, 1998, ALIMENT PHARM THERAP, V12, P439
[2]  
Bigard MA, 1998, ALIMENT PHARM THER, V12, P383
[3]  
BOLUKBAS F, 2001, TURK J GASTROENTE S1, V12, P88
[4]  
BOLUKBAS F, 2001, TURK J GASTROENTE S1, V12, P87
[5]  
Catalano F, 1998, ALIMENT PHARM THERAP, V12, P59
[6]  
CHEY WD, 1997, CONTEMP, V9, P52
[7]   Omeprazole-amoxycillin versus omeprazole-amoxycillin-clarithromycin in the eradication of Helicobacter pylori [J].
Delchier, JC ;
Elamine, I ;
Goldfain, D ;
Chaussade, S ;
Barthelemy, P ;
Idstrom, JP .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1996, 10 (03) :263-268
[8]  
DELTENRE M, 1995, EUR J GASTROEN HEPAT, V7, pS39
[9]  
ERGUN Y, 2002, TURK J GASTROENTE S1, V13, P86
[10]   What are the treatment goals for Helicobacter pylori infection? [J].
Fennerty, MB .
GASTROENTEROLOGY, 1997, 113 (06) :S120-S125